Article Information
vol. 5 no. 185 185ra68
- Received for publication April 16, 2013
- Accepted for publication May 2, 2013
Author Information
- Philip R. Dormitzer1,*,
- Pirada Suphaphiphat1,
- Daniel G. Gibson2,3,4,
- David E. Wentworth2,
- Timothy B. Stockwell2,
- Mikkel A. Algire2,
- Nina Alperovich2,
- Mario Barro5,
- David M. Brown2,
- Stewart Craig1,
- Brian M. Dattilo5,
- Evgeniya A. Denisova2,
- Ivna De Souza1,
- Markus Eickmann6,
- Vivien G. Dugan2,†,
- Annette Ferrari1,
- Raul C. Gomila1,7,
- Liqun Han1,
- Casey Judge1,
- Sarthak Mane1,
- Mikhail Matrosovich6,
- Chuck Merryman3,
- Giuseppe Palladino1,
- Gene A. Palmer1,
- Terika Spencer1,8,
- Thomas Strecker6,
- Heidi Trusheim8,
- Jennifer Uhlendorff6,
- Yingxia Wen1,
- Anthony C. Yee2,
- Jayshree Zaveri2,
- Bin Zhou2,
- Stephan Becker6,
- Armen Donabedian5,
- Peter W. Mason1,
- John I. Glass2,
- Rino Rappuoli1,7 and
- J. Craig Venter2,3,4
- 1Novartis Vaccines and Diagnostics, Cambridge, MA 02139, USA.
- 2The J. Craig Venter Institute, Rockville, MD 20850, USA.
- 3The J. Craig Venter Institute, San Diego, CA 92121, USA.
- 4Synthetic Genomics Inc., La Jolla, CA 92037, USA.
- 5Biomedical Advanced Research and Development Authority, U.S. Department of Health and Human Services, Washington, DC 20201, USA.
- 6Institut für Virologie, Philipps-Universität Marburg, D-35032 Marburg, Germany.
- 7Novartis Vaccines and Diagnostics, 53100 Siena, Italy.
- 8Novartis Vaccines and Diagnostics, Holly Springs, NC 25740, USA.
- ↵*Corresponding author. E-mail: philip.dormitzer{at}novartis.com